blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3684813

EP3684813 - AGONISTIC CD40 ANTIBODIES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  23.07.2021
Database last updated on 01.10.2024
FormerRequest for examination was made
Status updated on  26.06.2020
FormerThe international publication has been made
Status updated on  30.03.2019
Formerunknown
Status updated on  09.10.2018
Most recent event   Tooltip27.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
MAB Discovery GmbH
Forstenrieder Straße 8-14
82061 Neuried / DE
[2020/31]
Inventor(s)01 / FISCHER, Stephan
Alpspitzstr. 1
82362 Weilheim / DE
02 / BECKMANN, Karsten
Asternweg 37
85591 Vaterstetten / DE
 [2020/31]
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2020/31]Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
Application number, filing date18778857.519.09.2018
[2020/31]
WO2018EP75388
Priority number, dateEP2017019197419.09.2017         Original published format: EP 17191974
[2020/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019057792
Date:28.03.2019
Language:EN
[2019/13]
Type: A1 Application with search report 
No.:EP3684813
Date:29.07.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 28.03.2019 takes the place of the publication of the European patent application.
[2020/31]
Search report(s)International search report - published on:EP28.03.2019
ClassificationIPC:C07K16/28, A61K39/00
[2020/31]
CPC:
C07K16/2878 (EP,CN,EA,KR,US); A61K39/395 (KR); A61K39/3955 (CN);
A61K45/06 (CN); A61P35/00 (CN,KR,US); A61P35/02 (CN);
A61K2039/505 (EP,CN,EA,KR,US); C07K2317/33 (CN); C07K2317/56 (CN);
C07K2317/565 (EP,CN,EA,KR,US); C07K2317/732 (CN); C07K2317/75 (EP,EA,KR,US);
C07K2317/92 (CN) (-)
C-Set:
A61K39/3955, A61K2300/00 (CN)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/31]
TitleGerman:AGONISTISCHE CD40-ANTIKÖRPER[2020/31]
English:AGONISTIC CD40 ANTIBODIES[2020/31]
French:ANTICORPS CD40 AGONISTES[2020/31]
Entry into regional phase06.04.2020National basic fee paid 
06.04.2020Designation fee(s) paid 
06.04.2020Examination fee paid 
Examination procedure06.04.2020Examination requested  [2020/31]
06.04.2020Date on which the examining division has become responsible
27.10.2020Amendment by applicant (claims and/or description)
23.07.2021Despatch of a communication from the examining division (Time limit: M04)
24.11.2021Reply to a communication from the examining division
22.07.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
30.09.2020Renewal fee patent year 03
31.08.2021Renewal fee patent year 04
31.08.2022Renewal fee patent year 05
31.08.2023Renewal fee patent year 06
27.08.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]US2006062784  (GRANT STEVEN [GB], et al);
 [A]US2006093600  (BEDIAN VAHE [US], et al);
 [A]US7338660  (BEDIAN VAHE [US], et al);
 [XDY]US2012121585  (HEUSSER CHRISTOPH [CH], et al);
 [Y]WO2017009473  (UCB BIOPHARMA SPRL [BE]);
 [XY]US2017088624  (FRANSSON JOHAN [CA], et al);
 [E]EP3401332  (MAB DISCOVERY GMBH [DE]);
by applicantWO2010108127
 US2018118843
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.